

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

Application No.: Based on PCT/JP03/08690
 Filed: Intl. Filing 09 JULY 2003
 1st Inventor: Yuji MATSUZAWA
 For: Novel Proteins and Use Thereof
 Atty. Dkt. No. 3083 USOP

Art Unit: tba
 Examiner: tba
 Allowed:
 Batch:
 Paper No.:

Information Disclosure Statement

MAIL STOP PCT
 P.O. Box 1450
 Commissioner for Patents
 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Form PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated: 1/10/05

(847) 383-3372
 (847) 383-3391



Mark Chao, Ph.D., Reg. No. 37,293
 Elaine M. Ramesh, Ph.D., Reg. No. 43,032
 Attorney for Applicants
 Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
 Intellectual Property Department
 475 Half Day Road
 Lincolnshire, IL 60069 USA

#3

10 JAN 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

10/520783

Application Number	Based on PCT/JP03/08690
Filing Date	Intl Date 09 JULY 2003
First Named Inventor	Yuji MATSUZAWA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3083 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A1	ERDING HU, et al., "AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity", The Journal of Biological Chemistry, (1996), pp. 10697-10703, Vol. 271, No. 18	
	A2	SYLVAIN BAULANDE, et al., "Adiponutrin, a Transmembrane Protein Corresponding to a Novel Dietary- and Obesity-linked mRNA Specifically Expressed in the Adipose Lineage", The Journal of Biological Chemistry, (2001), pp. 33336-33344, Vol. 276, No. 36	
	A3	KEE-HONG KIM, et al., "A Cysteine-rich Adipose Tissue-specific Secretory Factor Inhibits Adipocyte Differentiation", The Journal of Biological Chemistry, (2001), pp. 11252-11256, Vol. 276, No. 14	
	A4	HIROMICHI TSURUGA, et al., "Identification of Novel Membrane and Secreted Proteins Upregulated during Adipocyte Differentiation", Biochemical and Biophysical Research Communications 272, (2000), pp. 293-297	
	A5	IICHIRO SHIMOMURA, et al., "Enhanced Expression of PAI-1 in Visceral Fat: Possible Contributor to Vascular Disease in Obesity", Nature Medicine, (1996), pp. 800-803, Vol. 2, No. 7	
	A6	YUKIO ARITA, et al., "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity", Biochemical and Biophysical Research Communications 257(1999), pp. 79-83	
	A7	KEN KISHIDA, et al., "Aquaporin Adipose, a Putative Glycerol Channel in Adipocytes", The Journal Biochemical Chemistry, (2000), pp. 20896-20902, Vol. 275, No. 27	
	A8	KAZUHISA MAEDA, et al., Analysis of an Expression Profile of Genes in the Human Adipose Tissue", Gene 190, (1997), pp. 227-235	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.